3.03BMarket Cap
LossP/E TTM
Key Figures
43.650Open
44.990High
1.70MVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
2.69%Turnover Ratio
42.190Prev. Close
43.000Low
53.29MTurnover
LossP/E Static
18.41P/B
0.00%Div Yield TTM
-30.18%ROA
71.50052wk High
0.71Volume Ratio
-239.56MNet Profit
63.03MShares
-3.4918EPS TTM
0.72Beta
-228.24%ROE
7.76052wk Low
4.72%Amplitude
94.01%Gross Margin
3.03BMarket Cap
0.32Reward/Risk
6.27%Risk Rate
Currency: USD Updated: 2026-07-31 Key Insights
Uniqure NV's fundamentals are relatively healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 104 out of 385 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 65.62.In the medium term, the stock price is expected to trend up.Despite a good stock market performance over the past month, the company shows weak fundamentals and technicals, which don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Uniqure NV Highlights
StrengthsRisks
Uniqure NV News
More news coming soon, stay tuned...
Earnings Forecast
Strong Buy
Buy
Hold
Sell
Strong Sell
Ionis Pharmaceuticals Inc
IONS
26
Indicators
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Uniqure NV Info
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.
Ticker SymbolQURE
CompanyUniqure NV
CEOKapusta (Matthew)
Websitehttps://www.uniqure.com/
Shareholders
FAQs
What is the current price of Uniqure NV (QURE)?
The current price of Uniqure NV (QURE) is 43.63.
What is the symbol of Uniqure NV?
The ticker symbol of Uniqure NV is QURE.
What is the 52-week high of Uniqure NV?
The 52-week high of Uniqure NV is 71.50.
What is the 52-week low of Uniqure NV?
The 52-week low of Uniqure NV is 7.76.
What is the market capitalization of Uniqure NV?
The market capitalization of Uniqure NV is 2.75B.
Is Uniqure NV (QURE) currently rated as Buy, Hold, or Sell?
According to analysts, Uniqure NV (QURE) has an overall rating of Buy, with a price target of 65.62.
What is the Earnings Per Share (EPS TTM) of Uniqure NV (QURE)?
The Earnings Per Share (EPS TTM) of Uniqure NV (QURE) is -3.46.
